White House Adds Fifth CBD Policy Meeting for April 7 With OCan Group
- A fifth White House meeting has been scheduled for April 7 to discuss the FDA’s forthcoming “Cannabidiol (CBD) Products Compliance and Enforcement Policy.”
- Four prior stakeholder meetings with representatives from the hemp and marijuana industries were held on April 1 and 2 as part of the review process.
- The meetings, overseen by the Office of Information and Regulatory Affairs, allow outside parties to engage with officials before the FDA’s policy is finalized.
- The policy is drawing significant attention amid ongoing federal actions on cannabis, including an upcoming ban on intoxicating hemp products and potential cannabis rescheduling.
A fifth White House meeting has now been scheduled as federal officials continue reviewing a forthcoming Food and Drug Administration policy on cannabidiol (CBD) products.
According to the Office of Information and Regulatory Affairs calendar, OCan Group, LLC is set to meet with officials on April 7 at 2:30 p.m. regarding the FDA’s unpublished “Cannabidiol (CBD) Products Compliance and Enforcement Policy.” The meeting request lists Brett Goldman as the requester’s representative.
The newly added session comes after four other stakeholder meetings were already placed on the calendar for April 1 and April 2. Those earlier meetings involved David Heldreth of Panacea Plant Sciences, Trent Woloveck of Jushi Holdings, Mackie Barch of Story Cannabis and Iowa hemp farmer Earl Ramey.
With the addition of the April 7 meeting, the number of scheduled discussions tied to the CBD policy has now risen to five.
The meetings are part of the White House review process for federal actions considered by OIRA, a division within the Office of Management and Budget. That process gives outside parties an opportunity to speak directly with officials while a proposal is under review, often before final guidance is released.
The FDA document at the center of the meetings has not yet been made public, but its title indicates it will address compliance and enforcement for CBD products. That has drawn attention across the hemp and marijuana industries, where businesses, advocates and regulators have spent years waiting for clearer federal direction on how hemp-derived cannabinoids will be treated.
The four previously scheduled meetings drew interest because they included voices from both the hemp industry and the marijuana sector. The addition of OCan Group suggests interest in the pending policy continues to grow as the review moves forward.
The flurry of meetings comes at a time of heightened federal attention on cannabis, with a federal ban on intoxicating hemp products set to take effect in November and a final ruling on cannabis rescheduling expected at any time.